In contrast, CD14+ monocytes and CD163+ and CD68+ macrophages predominated in the immune landscape of the FGF23-secreting tumour microenvironment, accounting for 30.74%, 23.23%, and 16.96% of all detectable immunopositive tumour cells, respectively (Figure 5). This evidence concerns the gene FGF23 and neoplasm.